Brain-computer interface "unicorn" Qiangnao Technology has completed a 2 billion yuan financing round, making it the second largest after Musk's Neuralink.

Brain-computer interface "unicorn" Qiangnao Technology has completed a 2 billion yuan financing round, making it the second largest after Musk's Neuralink.

Leading company in the brain-computer interface field, Strong Brain Technology, recently completed a financing round of approximately 2 billion yuan, setting the world's second-largest fundraising record in this sector after Neuralink, and marking that the commercialization of this frontier technology is now strongly backed by top-tier capital.

According to The Paper’s report on January 6, the investor lineup for this round is impressive, led by renowned institutions IDG and Walden International, and joined by strategic investors in the industrial chain such as Lens Technology and Will Semiconductor. This massive capital injection comes as the global brain-computer interface sector heats up, showing that market investors’ confidence in technology transitioning from lab to large-scale application is rapidly increasing.

Driven by this news and Elon Musk's statement that Neuralink will start mass production in 2026, the capital markets reacted dramatically. Since the opening of the markets in 2026, brain-computer interface concept stocks have performed strongly—stocks like Beiyikang and Sanbo Brain Science have seen consecutive limit-ups, while Sinomed, Guangzhou Bio, Aipeng Medical, Meihau Medical, Xiangyu Medical, and Lepu Medical hit the 20CM limit. Investors are reevaluating the business prospects and valuation space of this key technology field.

The deep involvement of supply chain giants such as Lens Technology further validates the trend of the industry crossing from R&D to mass production. As the exclusive provider of Strong Brain Technology’s core hardware modules, Lens Technology announced it is actively seeking more cooperation thanks to its precise manufacturing abilities, showing that upstream and downstream sectors of the industry chain are accelerating integration.

Top-tier Capital and Industry Giants Join Forces for Investment

Media reports indicate this round of financing combines both financial investors and industrial capital support. Investors include IDG Capital and Walden International, founded by Intel CEO Frank Lin. Additionally, "Apple supply chain" giant Lens Technology, Lingyi iTech, as well as strategic investors Will Semiconductor, Runze Technology, Huazhu Group, and Tal Education Group have all joined in. The list also features top family offices from Hong Kong and the US.

The deep binding of the industrial chain is a highlight of this financing round. On January 6, Lens Technology confirmed in response to investor inquiries that it is a strategic investor in Strong Brain Technology and exclusively undertakes mass production of its core hardware modules. In November 2025, Lens Technology and Strong Brain jointly donated a large number of smart bionic limbs to Hunan Province’s Disabled Persons' Federation, all with core modules produced by Lens. This "capital + manufacturing" cooperation mode provides supply chain assurance for the scaled roll-out of brain-computer interface products.

As a unicorn in the brain-computer interface sector, Strong Brain Technology, along with DeepSeek and Unitree Robotics, is known as one of "Hangzhou’s Six Little Dragons." The company focuses on R&D of brain-computer interface products and is one of the few globally to have achieved scale mass production of such products. It has received FDA accreditation in the US and CE certification in Europe, and ranks among the top in industry R&D investment.

The trigger for this round of market excitement is the latest development from its key competitor Neuralink. On January 1, Musk announced Neuralink will begin mass production of devices in 2026 and advance fully automated surgery solutions; then, on January 3, he expressed confidence in helping people with paralysis regain full body function. These two major announcements validate the technical feasibility and directly drove the stock surge of concept companies like Beiyikang, Xiangyu Medical, and Meihau Medical at the start of trading in 2026.

Strong Brain Technology was founded in 2015 by Harvard alumnus Han Bicheng. Its technical approach focuses on non-invasive brain-computer interfaces, creating signal connections between the brain and external devices to provide solutions for rehabilitation of the disabled and treatment of brain diseases. Han Bicheng previously stated that brain-computer interfaces are transitioning from laboratory research to a key technology impacting daily life, making it possible to “make the human brain transparent” in the future.

Commercial Deployment and IPO Prospects

Regarding commercial applications, Strong Brain Technology’s core product, the “super sensor”, can detect faint brain signals without opening the skull and convert them into neural signals to control external devices. Currently, its products can help individuals with limb disabilities achieve functions like running and high-difficulty sports. Han Bicheng proposed that in the next 5 to 10 years, the plan is to help one million people with limb disabilities regain mobility and help ten million patients with Alzheimer’s, autism, or insomnia rehabilitate.

As for the next step in the capital market, according to Bloomberg, Strong Brain Technology may pursue an initial public offering (IPO) in Hong Kong or mainland China. Insiders told media that the company has begun preparing listing documents, though the location and details are not yet finalized and discussions remain uncertain.

With China increasing investment in brain science and brain-computer interface sectors, the launch of the so-called "Brain Project", and leading companies like Strong Brain Technology having secured funding, this sector is rapidly entering a new stage of technological realization and commercial explosion.

Risk Warning and DisclaimerThe market entails risk, and investment should be undertaken with caution. This article does not constitute personal investment advice, nor does it take into consideration the special investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions herein suit their specific circumstances. Investment based on this information is at one’s own risk.